Page last updated: 2024-09-03

iguratimod and Bone Loss, Perimenopausal

iguratimod has been researched along with Bone Loss, Perimenopausal in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Jian, LL; Li, CH; Liu, XY; Ma, ZZ; Sun, L; Wang, XY; Yao, ZQ; Zhao, JX	1

Other Studies

1 other study(ies) available for iguratimod and Bone Loss, Perimenopausal

Article	Year
Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways. International immunopharmacology, 2021, Volume: 90 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Differentiation; Cells, Cultured; Chromones; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; p38 Mitogen-Activated Protein Kinases; RANK Ligand; Rats, Wistar; Signal Transduction; Sulfonamides; Tumor Necrosis Factor-alpha	2021

Article

Year

Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.

International immunopharmacology, 2021, Volume: 90

Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Differentiation; Cells, Cultured; Chromones; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; p38 Mitogen-Activated Protein Kinases; RANK Ligand; Rats, Wistar; Signal Transduction; Sulfonamides; Tumor Necrosis Factor-alpha

2021